Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin Plus Gemcitabine in Metastatic Solid Tumors
NCT02235688Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2014
- Primary completion
- Jan 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldoxorubicin in metastatic solid tumor, sponsored by ImmunityBio, Inc. Primary endpoint: Safety Measures at 14 months. Started Aug 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT02235688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235688.